Men2 Phenotype Unclassified Cn311636
An inherited condition causing tumors in hormone-producing glands. Requires genetic testing to determine specific type and associated cancer risks.
Key facts at a glance
- ICD-10
- E34.9
- ICD-11
- 5A00.0
- Body system
- endocrine
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(endocrine)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Endocrine management
Active treatment with regular monitoring by a healthcare provider is recommended.
Prophylactic thyroidectomy
Early surgical removal of the thyroid gland to prevent medullary thyroid carcinoma development in MEN2 patients. The timing is based on genetic testing results and specific RET mutation analysis to optimize outcomes.
Adrenalectomy for pheochromocytoma
Surgical removal of adrenal tumors that produce excess catecholamines, typically performed using minimally invasive approaches when feasible to minimize recovery time and complications.
Additional treatment options
Tyrosine kinase inhibitor therapy
Targeted therapy using FDA-approved kinase inhibitors such as vandetanib or cabozantinib for patients with metastatic medullary thyroid cancer associated with MEN2 syndrome.
medicationGenetic testing and counseling
Comprehensive germline RET gene testing for affected individuals and family members to determine carrier status and guide personalized surveillance and intervention timing.
procedureMultidisciplinary tumor surveillance
Regular screening protocol including annual calcitonin testing, neck imaging, metanephrine levels, and periodic cross-sectional imaging to detect tumor development or recurrence early.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Men2 Phenotype Unclassified Cn311636?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Men2 Phenotype Unclassified Cn311636. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy